Why stigma is a launch risk in rare disease – and what commercial leaders can do about it
March 2, 2026 |
Rare disease launches are complex by nature. Yet one of the most consistent risks we see is rarely treated as a launch issue at all: stigma.
Rare disease launches are complex by nature. Yet one of the most consistent risks we see is rarely treated as a launch issue at all: stigma.
Stigma is not a reputational concern or a social footnote. In rare disease, it directly affects diagnosis, belief, uptake, advocacy, adherence and longterm brand trust. It shapes whether patients are believed, whether caregivers persist, and whether healthcare professionals act. If launch excellence is about preparing markets to receive and sustain innovation, then stigma cannot sit downstream as a communications task. It must be addressed systemically, from the start.
Start with disease strategy grounded in lived reality
Launch excellence begins well before product visibility. At the disease strategy and prelaunch insight stage, stigma needs to be recognised as a core disease barrier, alongside misdiagnosis and access.
Effective approaches include:
- Treating stigma as part of disease burden, not context.
- Using patient and caregiver insight to identify where stigma blocks the pathway (e.g. disbelief, hiding symptoms, delayed care).
- Segmenting stigma across social, institutional and internalised dimensions.
Stronger alignment across medical, access and commercial teams is critical and a reflection of behavioural and social barriers, not just clinical ones. This in turn enables sharper, more targeted disease narratives and earlier identification of barriers to uptake.
Build belief and trust before product visibility
Early stakeholder engagement is where belief is either built or quietly eroded. Patients, caregivers and advocates should be engaged as strategic partners, not spokespeople validating predetermined decisions.
Effective approaches include:
- Cocreating disease framing and language to avoid stereotypes or blame.
- Aligning global and local teams early on nonstigmatizing narratives.
- Designing engagement to support launch, not challenge it.
Patient voices shape strategy and can help define credible, trusted disease positioning and reduce the risk of disengagement.
Move from awareness to understanding
In rare disease, awareness is rarely the problem. Understanding is. Particularly for invisible conditions, stigma thrives where understanding breaks down.
Launch-ready disease education can:
- Prioritises understanding and visibility over information volume.
- Supports plainlanguage tools patients and families can use in schools, workplaces and communities.
- Normalises lived experience rather than exceptionalising it.
The aim here is to enable earlier diagnosis conversations and reduce the emotional burden on patients to constantly explain themselves.
Address institutional stigma through medical strategy
Stigma does not stop at the clinic door. Disbelief, dismissal and misinterpretation remain significant barriers within healthcare systems.
Launch excellence requires medical strategy to:
- Address institutional stigma directly.
- Integrate lived experience insight into medical education and engagement.
- Position patient experience as outcome-relevant, not “soft context”.
If we can facilitate more productive HCP-patient dialogue so that the medical strategy improves how patients are heard, not just how disease is treated.
Build brands and platforms that endure – within culture, not above it
All too often we see rare brands being built almost exclusively around clinical benefits due to the needs, without sufficient consideration of the cultural and societal context in which the brand will live.
In rare disease, stigma is part of that context. Brands do not enter a neutral environment – they enter systems shaped by belief, bias, misunderstanding and lived experience.
Launch-leading brands:
- Anchor brand platforms in a clear launch strategy, informed by cultural and stigma realities.
- Look beyond rational proof points to address belief, trust and perception.
- Build brands that acknowledge the wider environment patients, caregivers and HCPs operate within.
This delivers brand platforms that resonate culturally, not just clinically, with a stronger coherence between disease understanding, brand meaning and engagement.
Sustain confidence through patient and caregiver ecosystems
Postlaunch success is sustained through ecosystems, not campaigns. Caregivers must be treated as a priority audience, not a secondary one.
Effective ecosystems:
- Reduce guilt, blame and social isolation.
- Support longterm confidence and advocacy.
- Evolve with patient needs over time.
This drives stronger longterm engagement, higher trust and brand advocacy and reduced dropoff driven by emotional burden.
A final thought
Launch excellence in rare disease requires treating stigma as a launch risk, not a reputational issue. Organisations that embed stigma reduction across insight, strategy, engagement and support are better positioned to accelerate diagnosis, build belief and trust, and enable sustainable uptake.
If you’d like to explore how datadriven insight can be used to uncover stigmadriven barriers and inform launch excellence strategies, get in touch. We’d welcome the opportunity to share how we help rare disease teams prepare markets to receive innovation – and sustain it.
Find out more and download our report ‘Stigma: The Invisible Multiplier of Burden in Rare Disease’ at havasrarenext.com
Sarah Mikhailov, Managing Director, Havas Life London
This content was provided by Havas Life London
Company Details
Latest Content from Havas Life London
Why stigma is a launch risk in rare disease – and what commercial leaders can do about it
Rare disease launches are complex by nature. Yet one of the most consistent risks we see is rarely treated as a launch issue at all: stigma.
Rare, But Out There: The art of reaching rare disease patients through understanding human experience
Director Helena Wright talks about the importance of understanding the beliefs, emotional drivers and cultural factors that underpin the experience of living with a rare disease, as we mark Rare...
The patient voice
We believe that listening to people's lived experiences are vital components of our work.
Rare and Orphan Diseases
Why we need authentic and personalised communications in the evolving rare disease space. By Sarah Mikhailov, Managing Director, Brand at Havas Life Medicom
Creating content to trigger behaviour change
As part of the development of content and communication strategies in healthcare, we mine for insights into audience behaviours – identifying what HCPs or patients think and how they act;...
Havas Life Medicom named Agency Digital Team and leads agency wins at PM Digital Awards
Wins included three gold, three silver and two bronze across multiple categories
2020 – a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith
When community can inspire a social media movement
Natalie Karaminas, Account Director, PR & Creative Communications at Havas Life Medicom, shares the value of social media in building online communities to spark a movement